"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 5 | 1 | 6 |
| 2001 | 4 | 0 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 1 | 4 |
| 2006 | 6 | 6 | 12 |
| 2007 | 5 | 3 | 8 |
| 2008 | 7 | 1 | 8 |
| 2009 | 5 | 3 | 8 |
| 2010 | 1 | 2 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 1 | 3 |
| 2014 | 5 | 1 | 6 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Risk Factors Control and Early Recurrent Cerebral Infarction in Patients with Symptomatic Intracranial Atherosclerotic Disease. J Stroke Cerebrovasc Dis. 2021 Sep; 30(9):105914.
-
Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
-
Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020 04; 31(2):108-110.
-
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
-
Associations between BMI, waist circumference, central obesity and outcomes in type II diabetes mellitus: The ACCORD Trial. J Diabetes Complications. 2020 03; 34(3):107499.
-
Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019 12; 39(12):2457-2467.
-
Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J Diabetes Complications. 2019 07; 33(7):468-472.
-
Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):673-678.
-
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metab. 2017 02 07; 25(2):358-373.
-
Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat. Pediatr Surg Int. 2016 Dec; 32(12):1193-1200.